India consults on data requirements for drug trials, BA/BE studies
This article was originally published in SRA
Executive Summary
India's Central Drugs Standard Control Organization has issued a draft guideline explaining proposed requirements for submission of chemical and pharmaceutical information, including stability study data, for the approval of clinical trial and bio-availability/bio-equivalence studies1.